Analyst Price Targets — NTRA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 14, 2026 10:52 am | — | Canaccord Genuity | $330.00 | $272.89 | TheFly | Natera price target raised to $330 from $285 at Canaccord |
| July 9, 2026 10:58 am | — | Morgan Stanley | $310.00 | $274.39 | TheFly | Natera price target raised to $310 from $250 at Morgan Stanley |
| July 6, 2026 12:45 pm | — | Evercore ISI | $300.00 | $281.26 | TheFly | Natera price target raised to $300 from $270 at Evercore ISI |
| June 29, 2026 11:00 am | Subbu Nambi | Guggenheim | $290.00 | $261.91 | TheFly | Natera price target raised to $290 from $270 at Guggenheim |
| June 24, 2026 5:00 pm | — | BTIG | $275.00 | $260.72 | TheFly | Natera price target raised to $275 from $270 at BTIG |
| June 24, 2026 8:50 am | — | UBS | $260.00 | $234.76 | TheFly | Natera price target lowered to $260 from $280 at Barclays |
| June 23, 2026 7:48 pm | — | BTIG | $270.00 | $234.76 | StreetInsider | Natera (NTRA) PT Raised to $270 at BTIGMember Login |
| June 11, 2026 8:06 pm | Dan Leonard | RBC Capital | $275.00 | $219.23 | StreetInsider | RBC Capital Starts Natera (NTRA) at Outperform |
| June 5, 2026 6:33 am | Evie Koslosky | Goldman Sachs | $245.00 | $222.10 | StreetInsider | Goldman Sachs Starts Natera (NTRA) at Neutral |
| May 12, 2026 10:41 am | — | Piper Sandler | $249.00 | $199.14 | TheFly | Natera price target raised to $249 from $240 at Piper Sandler |
Latest News for NTRA
Allspring Global Investments Holdings LLC grew its holdings in Natera, Inc. (NASDAQ: NTRA) by 2.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 463,477 shares of the medical research company's stock after purchasing an additional 8,979 shares during the quarter.
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today highlighted the impact of a final local coverage determination (LCD) for molecular testing for solid organ allograft rejection: L40060.The LCD strengthens coverage for Prospera in the surveillance settings. The new policy, which is expected to take effect on August 30, 2026, specifically…
It may not be a familiar name, but Natera has provided better returns than Nvidia over the past 12 months.
Natera's Signatera became the first personalized MRD test for solid tumors to earn EU IVDR certification, supporting broader expansion across Europe.
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.